Yoon Hee Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoon Hee Lee has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Gun Oh Chong
Clinical Omics Institute, Kyungpook National University
6 shared publications - Dae Gy Hong
Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
3 shared publications - Jong Mi Kim
Department of Obstetrics and Gynecology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu 41404, Republic of Korea
3 shared publications - Juhun Lee
Department of Obstetrics and Gynecology, School of Medicine Kyungpook National University Daegu Republic of Korea
2 shared publications - Sang-Woo Lee
Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea
2 shared publications - Shin Young Jeong
Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu 41404, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2691
Diagnostic Performance of Post-Treatment F-18 FDG PET/CT for Detecting Recurrent Cervical Cancer
Background/Objectives: Cervical cancer recurrence after definitive treatment remains a major clinical challenge, and early detection may improve patient outcomes. This study evaluated the diagnostic performance of fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) for detecting recurrent cervical cancer according to clinical context. Methods: We retrospectively reviewed 1727 post-treatment PET/CT examinations obtained from 659 patients who achieved a complete response after definitive treatment between 2005 and 2024. After excluding 15 examinations that detected second primary malignancies, the recurrence-specific analysis included 1712 examinations from 654 patients. PET/CT findings were classified as true positive, true negative, false positive, or false negative based on histopathology or serial imaging follow-up. Generalized estimating equations were used to account for within-patient clustering. Subgroup analyses were performed according to histology, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage, interval from treatment completion to PET/CT, and clinical context. Results: Of the 1712 examinations, 136 (7.9%) were true positive, 1525 (89.1%) were true negative, 43 (2.5%) were false positive, and 8 (0.5%) were false negative. Overall sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 94.4%, 97.3%, 76.0%, 99.5%, and 97.0%, respectively. Diagnostic performance was similar across histologic subtypes and FIGO stages. In routine follow-up settings without clinical suspicion of recurrence, PET/CT showed a high NPV (100.0%), whereas examinations performed for clinically suspected recurrence showed a high PPV (96.5%). Conclusions: These findings suggest that the diagnostic interpretation and clinical utility of post-treatment PET/CT may vary according to the clinical setting.
- 23 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2691
Open AccessDiagnostic Performance of Post-Treatment F-18 FDG PET/CT for Detecting Recurrent Cervical Cancer
Background/Objectives: Cervical cancer recurrence after definitive treatment remains a major clinical challenge, and early detection may improve patient outcomes. This study evaluated the diagnostic performance of fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) for detecting recurrent cervical cancer according to clinical context. Methods: We retrospectively reviewed 1727 post-treatment PET/CT examinations obtained from 659 patients who achieved a complete response after definitive treatment between 2005 and 2024. After excluding 15 examinations that detected second primary malignancies, the recurrence-specific analysis included 1712 examinations from 654 patients. PET/CT findings were classified as true positive, true negative, false positive, or false negative based on histopathology or serial imaging follow-up. Generalized estimating equations were used to account for within-patient clustering. Subgroup analyses were performed according to histology, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage, interval from treatment completion to PET/CT, and clinical context. Results: Of the 1712 examinations, 136 (7.9%) were true positive, 1525 (89.1%) were true negative, 43 (2.5%) were false positive, and 8 (0.5%) were false negative. Overall sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 94.4%, 97.3%, 76.0%, 99.5%, and 97.0%, respectively. Diagnostic performance was similar across histologic subtypes and FIGO stages. In routine follow-up settings without clinical suspicion of recurrence, PET/CT showed a high NPV (100.0%), whereas examinations performed for clinically suspected recurrence showed a high PPV (96.5%). Conclusions: These findings suggest that the diagnostic interpretation and clinical utility of post-treatment PET/CT may vary according to the clinical setting.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (4) , 298-304
Comparison of Colorimetric LAMP and PCR for High-risk HPV Detection: Implications for Cervical Cancer Screening
Objective: Cervical cancer, primarily caused by human papillomavirus (HPV) infection, is commonly detected using polymerase chain reaction (PCR)-based assays. However, these methods are time-consuming and require specialized instrumentation. This study evaluated the diagnostic performance of the loop-mediated isothermal amplification (LAMP) assay as a rapid alternative for HPV detection compared with conventional PCR testing. Methods: This study included 933 nonpregnant women aged ≥19 years who underwent HPV testing for cervical cancer screening or follow-up. The HPV panel included 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Cervical swab samples underwent nucleic acid extraction followed by LAMP amplification using type-specific primers. Reactions were performed at 63 °C for 35 minutes, and results were interpreted colorimetrically (blue for positive, purple for negative). Results: Compared with PCR, the LAMP assay showed a sensitivity of 97.8% (95% CI: 94.4–100.0) for HPV types 16 and 18 and 100.0% (95% CI: 98.8–100.0) for the remaining high-risk types. Specificity across all types was 100.0% (95% CI: 98.8–100.0). The overall diagnostic accuracy was 99.5% (95% CI: 99.0–100.0). When all 14 HPV types were analyzed collectively, clinical sensitivity and specificity were 99.4% and 100.0%, respectively. Conclusions: The LAMP assay provides a rapid, simple, and accurate method for HPV detection and may serve as a useful point-of-care screening tool, particularly in resource-limited settings.
- 7 August 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (4) , 298-304
Open AccessComparison of Colorimetric LAMP and PCR for High-risk HPV Detection: Implications for Cervical Cancer Screening
Objective: Cervical cancer, primarily caused by human papillomavirus (HPV) infection, is commonly detected using polymerase chain reaction (PCR)-based assays. However, these methods are time-consuming and require specialized instrumentation. This study evaluated the diagnostic performance of the loop-mediated isothermal amplification (LAMP) assay as a rapid alternative for HPV detection compared with conventional PCR testing. Methods: This study included 933 nonpregnant women aged ≥19 years who underwent HPV testing for cervical cancer screening or follow-up. The HPV panel included 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Cervical swab samples underwent nucleic acid extraction followed by LAMP amplification using type-specific primers. Reactions were performed at 63 °C for 35 minutes, and results were interpreted colorimetrically (blue for positive, purple for negative). Results: Compared with PCR, the LAMP assay showed a sensitivity of 97.8% (95% CI: 94.4–100.0) for HPV types 16 and 18 and 100.0% (95% CI: 98.8–100.0) for the remaining high-risk types. Specificity across all types was 100.0% (95% CI: 98.8–100.0). The overall diagnostic accuracy was 99.5% (95% CI: 99.0–100.0). When all 14 HPV types were analyzed collectively, clinical sensitivity and specificity were 99.4% and 100.0%, respectively. Conclusions: The LAMP assay provides a rapid, simple, and accurate method for HPV detection and may serve as a useful point-of-care screening tool, particularly in resource-limited settings.
- Open Access
- 30 November 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (Suppl) , S65-S72
Comparison of serum anti-Müllerian hormone between unilateral and bilateral ovarian endometriomas during follicular, luteal, and random menstrual phases: a retrospective study
Background: Over the last two decades, serum levels of anti-Müllerian hormone (AMH) have been shown to be reliable markers of ovarian reserve. This study aimed to compare baseline serum AMH levels and well-controlled clinical factors between patients with unilateral and bilateral ovarian endometriomas during the menstrual phase.Methods: We conducted a retrospective study. We enrolled 136 patients aged 18 to 36 years who were diagnosed with unilateral or bilateral ovarian endometriomas. Serum AMH levels of all patients and their latest two to three menstrual cycles were measured before surgery for ovarian endometriomas. The latest menstrual cycle length ranged from 26 to 30 days. Patients with irregular menstruation, a recent medication history of hormonal drugs other than oral contraceptive pills, a previous history of ovarian surgery, or any medical history influencing ovarian function were excluded. Results: Of the 136 patients, 76 (55.9%) had unilateral ovarian endometriomas and 60 (44.1%) had bilateral ovarian endometriomas. Serum AMH levels were not significantly different between the two groups in the follicular phase, luteal phase, or at any random time point. Conclusion: Serum AMH levels were not significantly different between unilateral and bilateral ovarian endometriomas in the follicular and luteal phases, or at any random time during the menstrual cycle when various confounding factors were excluded.
- 30 November 2023
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 40 (Suppl) , S65-S72
Open AccessComparison of serum anti-Müllerian hormone between unilateral and bilateral ovarian endometriomas during follicular, luteal, and random menstrual phases: a retrospective study
Background: Over the last two decades, serum levels of anti-Müllerian hormone (AMH) have been shown to be reliable markers of ovarian reserve. This study aimed to compare baseline serum AMH levels and well-controlled clinical factors between patients with unilateral and bilateral ovarian endometriomas during the menstrual phase.Methods: We conducted a retrospective study. We enrolled 136 patients aged 18 to 36 years who were diagnosed with unilateral or bilateral ovarian endometriomas. Serum AMH levels of all patients and their latest two to three menstrual cycles were measured before surgery for ovarian endometriomas. The latest menstrual cycle length ranged from 26 to 30 days. Patients with irregular menstruation, a recent medication history of hormonal drugs other than oral contraceptive pills, a previous history of ovarian surgery, or any medical history influencing ovarian function were excluded. Results: Of the 136 patients, 76 (55.9%) had unilateral ovarian endometriomas and 60 (44.1%) had bilateral ovarian endometriomas. Serum AMH levels were not significantly different between the two groups in the follicular phase, luteal phase, or at any random time point. Conclusion: Serum AMH levels were not significantly different between unilateral and bilateral ovarian endometriomas in the follicular and luteal phases, or at any random time during the menstrual cycle when various confounding factors were excluded.
- Open Access
- 23 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 6905
Comparison of Multi- and Single-Site Robotic Myomectomy Using the Da Vinci® SP Surgical System: A Propensity Score Matching Analysis
Objective: This study aimed to compare the surgical outcomes between robotic multi-site myomectomy (RMSM) and robotic single-site myomectomy (RSSM), using the da Vinci® SP surgical system and perform propensity score matching analysis to ensure inter-group comparability. Methods: This retrospective study included 105 patients who underwent either three-incision RMSM or RSSM using the da Vinci® SP surgical system. We retrospectively reviewed and compared surgical outcomes using 1:1 propensity score matching. Results: After 1:1 propensity score matching, there were no differences in the total operation time and estimated blood loss between the groups. The docking time (p < 0.0001) and duration of hospital stay (p = 0.0001) were significantly shorter in the RSSM group than in the RMSM group. Conclusions: The surgical outcomes of RSSM were comparable to those of RMSM. Moreover, compared to RMSM, RSSM using the da Vinci® SP surgical system has shorter docking and morcellation times, and duration of hospital stay.
- 23 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 6905
Open AccessComparison of Multi- and Single-Site Robotic Myomectomy Using the Da Vinci® SP Surgical System: A Propensity Score Matching Analysis
Objective: This study aimed to compare the surgical outcomes between robotic multi-site myomectomy (RMSM) and robotic single-site myomectomy (RSSM), using the da Vinci® SP surgical system and perform propensity score matching analysis to ensure inter-group comparability. Methods: This retrospective study included 105 patients who underwent either three-incision RMSM or RSSM using the da Vinci® SP surgical system. We retrospectively reviewed and compared surgical outcomes using 1:1 propensity score matching. Results: After 1:1 propensity score matching, there were no differences in the total operation time and estimated blood loss between the groups. The docking time (p < 0.0001) and duration of hospital stay (p = 0.0001) were significantly shorter in the RSSM group than in the RMSM group. Conclusions: The surgical outcomes of RSSM were comparable to those of RMSM. Moreover, compared to RMSM, RSSM using the da Vinci® SP surgical system has shorter docking and morcellation times, and duration of hospital stay.
- Open Access
- 9 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2659
Survival Impact of Residual Cancer Cells in Intraoperative Peritoneal Washes following Radical Hysterectomy for Cervical Cancer
Objective: Residual cancer cells (RCCs) contribute to cancer recurrence either because of tumor spillage or undetectable pre-existing micrometastatic tumor clones. We hypothesized that the pathologic evaluation of intraoperative peritoneal washes may reveal RCCs. The aim of this study was to evaluate the survival impact of RCCs identified in intraoperative peritoneal washes and their correlation with clinicopathologic parameters following radical hysterectomy for cervical cancer. Methods: A total of 229 patients with cervical cancer who underwent radical hysterectomy with pelvic and/or paraaortic lymphadenectomy were included. The intraoperative peritoneal washes after surgery were filtered through a strainer and the presence of tumor cells in the residual aspirate was determined. Univariate and multivariate analyses of clinicopathological parameters were performed to identify predictors of recurrence. Results: RCCs in intraoperative peritoneal washes were identified in 19 patients (8.3%). Multivariate analysis revealed that deep stromal invasion (hazard ratio [HR], 13.32; 95% confidence interval [CI], 1.81–98.27; p = 0.0111), lymph node metastasis (HR, 2.00; 95% CI, 1.01–3.99; p = 0.0482), and neoadjuvant chemotherapy (HR, 2.34; 95% CI, 1.89–4.61; p = 0.0139) were associated with tumor recurrence. However, the presence of RCCs was not associated with tumor recurrence (HR, 2.60; 95% CI, 0.74–9.11; p = 0.1352). Multiple logistic regression analysis revealed that RCCs were associated with neoadjuvant chemotherapy (odds ratio [OR], 0.22; 95% CI, 0.05–0.99; p = 0.0488) and large tumor size (OR, 4.16; 95% CI, 0.77–22.48; p = 0.0981). Conclusions: Although the presence of RCCs in intraoperative peritoneal washes do not significantly impact survival outcomes, there was a tendency of inferior survival outcomes in patients with RCCs. RCCs were associated with neoadjuvant chemotherapy and large tumor size.
- 9 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2659
Open AccessSurvival Impact of Residual Cancer Cells in Intraoperative Peritoneal Washes following Radical Hysterectomy for Cervical Cancer
Objective: Residual cancer cells (RCCs) contribute to cancer recurrence either because of tumor spillage or undetectable pre-existing micrometastatic tumor clones. We hypothesized that the pathologic evaluation of intraoperative peritoneal washes may reveal RCCs. The aim of this study was to evaluate the survival impact of RCCs identified in intraoperative peritoneal washes and their correlation with clinicopathologic parameters following radical hysterectomy for cervical cancer. Methods: A total of 229 patients with cervical cancer who underwent radical hysterectomy with pelvic and/or paraaortic lymphadenectomy were included. The intraoperative peritoneal washes after surgery were filtered through a strainer and the presence of tumor cells in the residual aspirate was determined. Univariate and multivariate analyses of clinicopathological parameters were performed to identify predictors of recurrence. Results: RCCs in intraoperative peritoneal washes were identified in 19 patients (8.3%). Multivariate analysis revealed that deep stromal invasion (hazard ratio [HR], 13.32; 95% confidence interval [CI], 1.81–98.27; p = 0.0111), lymph node metastasis (HR, 2.00; 95% CI, 1.01–3.99; p = 0.0482), and neoadjuvant chemotherapy (HR, 2.34; 95% CI, 1.89–4.61; p = 0.0139) were associated with tumor recurrence. However, the presence of RCCs was not associated with tumor recurrence (HR, 2.60; 95% CI, 0.74–9.11; p = 0.1352). Multiple logistic regression analysis revealed that RCCs were associated with neoadjuvant chemotherapy (odds ratio [OR], 0.22; 95% CI, 0.05–0.99; p = 0.0488) and large tumor size (OR, 4.16; 95% CI, 0.77–22.48; p = 0.0981). Conclusions: Although the presence of RCCs in intraoperative peritoneal washes do not significantly impact survival outcomes, there was a tendency of inferior survival outcomes in patients with RCCs. RCCs were associated with neoadjuvant chemotherapy and large tumor size.
- Open Access
- 16 June 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6) , 1878
Improving the Prognostic Performance of SUVmax in 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Using Tumor-to-Liver and Tumor-to-Blood Standard Uptake Ratio for Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
Objective: We sought to evaluate whether the 18F-fluorodeoxyglucose uptake normalization of the primary tumor to both the liver and blood pool and lymph nodes to both the liver and blood pool can enhance the discrimination for prognosis prediction in patients with cervical cancer. Methods: A total of 156 patients with cervical cancer (International Federation of Gynecology and Obstetrics stages IIB–IV) treated with concurrent chemoradiotherapy (CCRT) were enrolled. The maximum standardized uptake value (SUVmax) of tumor (tSUVmax) and the lymph node (nSUVmax) divided by the SUVmean of the liver (tumor-to-liver ratio (TLR) and node-to-liver (NLR)) and blood pool (tumor-to-blood ratio (TBR) and node-to-blood ratio (NBR)) were investigated. Univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS) were performed using clinical and metabolic parameters. A receiver operating characteristic curve analysis was performed to compare the accuracy of the metabolic parameters. Results: The multivariate analysis revealed that NLR (hazard ratio ((HR): 3.54; 95% confidence interval (CI): 1.53–8.19; p = 0.0032) and NBR (HR: 3.38; 95% CI: 1.02–11.19; p = 0.0457)) were independent prognostic factors for DFS, while TLR (HR: 4.16; 95% CI: 1.19–14.50; p = 0.0252), TBR (HR: 3.01; 95% CI: 1.04–8.70; p = 0.0415), NLR (HR: 4.84; 95% CI: 1.58–14.81; p = 0.0057), and NBR (HR: 6.87; 95% CI: 1.55–30.54; p = 0.0113) were significant prognostic factors for OS. The normalization of tSUVmax to the liver or blood pool enhanced the discrimination for prediction of recurrence (tSUVmax vs. TLR; p = 0.0056 and tSUVmax vs. TBR; p = 0.0099) and death (tSUVmax vs. TLR; p < 0.0001 and tSUVmax vs. TBR; p = 0.0001). Conclusions: The normalization of tSUVmax was an independent prognostic factor and improved the discrimination for the prediction of tumor recurrence and death in patients with locally advanced cervical cancer treated with CCRT.
- 16 June 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (6) , 1878
Open AccessImproving the Prognostic Performance of SUVmax in 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Using Tumor-to-Liver and Tumor-to-Blood Standard Uptake Ratio for Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
Objective: We sought to evaluate whether the 18F-fluorodeoxyglucose uptake normalization of the primary tumor to both the liver and blood pool and lymph nodes to both the liver and blood pool can enhance the discrimination for prognosis prediction in patients with cervical cancer. Methods: A total of 156 patients with cervical cancer (International Federation of Gynecology and Obstetrics stages IIB–IV) treated with concurrent chemoradiotherapy (CCRT) were enrolled. The maximum standardized uptake value (SUVmax) of tumor (tSUVmax) and the lymph node (nSUVmax) divided by the SUVmean of the liver (tumor-to-liver ratio (TLR) and node-to-liver (NLR)) and blood pool (tumor-to-blood ratio (TBR) and node-to-blood ratio (NBR)) were investigated. Univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS) were performed using clinical and metabolic parameters. A receiver operating characteristic curve analysis was performed to compare the accuracy of the metabolic parameters. Results: The multivariate analysis revealed that NLR (hazard ratio ((HR): 3.54; 95% confidence interval (CI): 1.53–8.19; p = 0.0032) and NBR (HR: 3.38; 95% CI: 1.02–11.19; p = 0.0457)) were independent prognostic factors for DFS, while TLR (HR: 4.16; 95% CI: 1.19–14.50; p = 0.0252), TBR (HR: 3.01; 95% CI: 1.04–8.70; p = 0.0415), NLR (HR: 4.84; 95% CI: 1.58–14.81; p = 0.0057), and NBR (HR: 6.87; 95% CI: 1.55–30.54; p = 0.0113) were significant prognostic factors for OS. The normalization of tSUVmax to the liver or blood pool enhanced the discrimination for prediction of recurrence (tSUVmax vs. TLR; p = 0.0056 and tSUVmax vs. TBR; p = 0.0099) and death (tSUVmax vs. TLR; p < 0.0001 and tSUVmax vs. TBR; p = 0.0001). Conclusions: The normalization of tSUVmax was an independent prognostic factor and improved the discrimination for the prediction of tumor recurrence and death in patients with locally advanced cervical cancer treated with CCRT.